Immuno-cell therapy for brain tumors

脑肿瘤的免疫细胞疗法

基本信息

  • 批准号:
    10390892
  • 负责人:
  • 金额:
    $ 61.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-01-01 至 2026-12-31
  • 项目状态:
    未结题

项目摘要

Abstract Glioblastoma (GBM) comprises >50% of all brain tumors in adults and is the most malignant form with a 5-year patient survival rate of 3.3%. Standard-of-care treatment involves maximal surgical resection followed by radiation and chemotherapy (temozolomide); however, as the poor survival rate indicates, these treatments have not been effective in preventing disease progression. Glioblastomas are highly heterogeneous with a small subpopulation of neural stem-like cells notorious for their resistance to conventional therapy and known to be responsible for tumor recurrence and patient death. Therapies that target tumor cells as well as glioma stem cells (GSCs), while sparing normal cells, would be highly beneficial for these patients. The unique capacity of mammalian olfactory epithelium in continuous replacing its olfactory receptor neurons by physiological turnover and following injury throughout life has been attributed to the olfactory ensheathing cells (OECs), a glial cell type that closely accompany the axons as they grow from the olfactory epithelium into the olfactory bulb. OECs migrate from the peripheral nervous system to the central nervous system (CNS), a critical process in the development and maintenance of the olfactory system and axonal extension after injury in neural regeneration. OECs release diffusible factors to attract neural progenitors into the rostral migratory stream and regulate their proliferation and differentiation and to differentiate neural stem cells leading to neurite extension. Owing to their strong ability to myelinate and guide axonal outgrowth, neuroprotective role, as well as their immunomodulatory and phagocytic properties, the therapeutic potential of OECs was evaluated against different neurological pathologies in the clinic and as a carrier for therapeutic transgene to glioma cells in culture, but their tropism and effect against gliomas in vivo were not studied. Recently, we showed for the first time that autologous transplantation of mouse OECs can target and deliver therapeutic transgenes to brain tumors upon intranasal administration, the natural route of OECs to CNS. In this proposal, we will build on this study and evaluate the potential use of OECs for glioblastoma stem cell therapy by regulating proliferation and/or differentiation of GSCs, making them susceptible to conventional therapies, reversing immune supression and activating anti-tumor immunity.
摘要 胶质母细胞瘤(GBM)占所有成人脑肿瘤的50%,是最恶性的形式,长达5年。 患者存活率为3.3%。标准治疗包括最大限度的手术切除,然后是 放疗和化疗(替莫唑胺);然而,正如低存活率所表明的那样,这些治疗 在预防疾病进展方面并不有效。胶质母细胞瘤具有高度的异质性。 神经干细胞亚群的一小部分,因其对常规疗法的抵抗而臭名昭著 对肿瘤复发和病人死亡负责。针对肿瘤细胞和胶质瘤的治疗方法 干细胞(GSCs)在保留正常细胞的同时,对这些患者将非常有益。独一无二的 哺乳动物嗅觉上皮持续替代其嗅觉感受器神经元的能力 在整个生命过程中,嗅鞘细胞的生理性转化和随后的损伤被归因于嗅鞘细胞 (OECs),一种神经胶质细胞类型,在轴突从嗅觉上皮生长到 嗅球。嗅鞘细胞从外周神经系统迁移到中枢神经系统(CNS), 嗅觉系统的发育和维持以及损伤后轴突延伸的关键过程 在神经再生方面。嗅鞘细胞释放扩散性因子吸引神经前体细胞进入吻部迁移 分流和调节它们的增殖和分化,并分化神经干细胞,导致 轴突延伸。由于它们强大的髓鞘形成和引导轴突生长的能力,神经保护作用, 以及它们的免疫调节和吞噬特性,评估了嗅鞘细胞的治疗潜力。 抗不同神经病理疾病的临床应用和作为治疗性转基因胶质瘤细胞的载体 但它们在体内的趋向性和抗胶质瘤作用尚未被研究。最近,我们为 第一次小鼠嗅鞘细胞自体移植可以靶向并将治疗性转基因输送到脑内 肿瘤通过鼻腔给药,这是嗅鞘细胞到达中枢神经系统的自然途径。在这项提议中,我们将以此为基础 嗅鞘细胞在胶质母细胞瘤干细胞治疗中的应用研究 和/或分化的GSCs,使其对传统疗法敏感,逆转免疫 抑制和激活抗肿瘤免疫。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BAKHOS A TANNOUS其他文献

BAKHOS A TANNOUS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BAKHOS A TANNOUS', 18)}}的其他基金

Radiation-induced targeted extracellular vesicles -based gene delivery for glioma therapy
放射诱导的基于细胞外囊泡的基因递送用于神经胶质瘤治疗
  • 批准号:
    9902892
  • 财政年份:
    2019
  • 资助金额:
    $ 61.49万
  • 项目类别:
Radiation-induced targeted extracellular vesicles -based gene delivery for glioma therapy
放射诱导的基于细胞外囊泡的基因递送用于神经胶质瘤治疗
  • 批准号:
    10058293
  • 财政年份:
    2019
  • 资助金额:
    $ 61.49万
  • 项目类别:
Screening for adjuvant gliobalstoma therapeutics
胶质母细胞瘤辅助治疗的筛选
  • 批准号:
    9127592
  • 财政年份:
    2016
  • 资助金额:
    $ 61.49万
  • 项目类别:
Screening for adjuvant gliobalstoma therapeutics
胶质母细胞瘤辅助治疗的筛选
  • 批准号:
    9244081
  • 财政年份:
    2016
  • 资助金额:
    $ 61.49万
  • 项目类别:
Blood-based assays for the detection of glioblastoma RNA biomarkers
用于检测胶质母细胞瘤 RNA 生物标志物的血液检测
  • 批准号:
    9149048
  • 财政年份:
    2015
  • 资助金额:
    $ 61.49万
  • 项目类别:
Detection of NSCLC-derived mutant RNA in platelets
血小板中 NSCLC 衍生突变 RNA 的检测
  • 批准号:
    8589148
  • 财政年份:
    2013
  • 资助金额:
    $ 61.49万
  • 项目类别:
Detection of NSCLC-derived mutant RNA in platelets
血小板中 NSCLC 衍生突变 RNA 的检测
  • 批准号:
    8692700
  • 财政年份:
    2013
  • 资助金额:
    $ 61.49万
  • 项目类别:
Screening for modulators of glioma stem cells differentiation
神经胶质瘤干细胞分化调节剂的筛选
  • 批准号:
    8452232
  • 财政年份:
    2013
  • 资助金额:
    $ 61.49万
  • 项目类别:
Screening for modulators of glioma stem cells differentiation
神经胶质瘤干细胞分化调节剂的筛选
  • 批准号:
    8605810
  • 财政年份:
    2013
  • 资助金额:
    $ 61.49万
  • 项目类别:
Glioblastoma stem cells therapy
胶质母细胞瘤干细胞治疗
  • 批准号:
    8308009
  • 财政年份:
    2009
  • 资助金额:
    $ 61.49万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 61.49万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了